|Cancer Therapeutics & Partnering Summit|
Oncology Partnering & Deal-Making
Complementary & Companion Diagnostics in Oncology
We invite you to attend the Oncology Partnering & Deal-Making Conference, which will take place September 28-29, 2017 in San Diego, CA. This event is a partnership and business development conference that provides an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations and learn about relevant issues in oncology that will affect the industry.
Experts in the field of oncology will present on the latest discoveries, novel technologies, business development trends, markets, innovative partnering for value creation, and landscape of Immuno-oncology. There will be a mix of presentations and interactive panel discussions so join your business development colleagues at this unique partnering forum!
Joint Plenary Sessions:
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Round Table Discussions
III. Ready, Set, Grow – New Company/Technology Pitch Competition
IV. Award Ceremony & Closing Keynote Session – Predictions for the Future
Oncology Partnering & Deal-Making
I. What sells in Oncology – New Targets, Models, Assays, etc.
II. Industry Partnering with Academic Groups & CROs to Advance Research
III. Oncology Perspectives from Venture Capital & Public Markets
IV. Technology Transfer & Licensing: Challenges & Opportunities
We hope to see you there!
The 2017 Advisory Committee
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Reaction Biology Corp. is a CRO that specializes in epigenetic and kinase HTS and profiling services. RBC’s radioisotope based assays feature the largest collection of kinase & epigenetic targets available to the industry, including more than 559 kinases, 100+ reader domains, >30 methyltransferases, all HDACs and SIRTs, demethylases and more. RBC also produces high quality epigenetic proteins that are available for purchase.
ACEA Biosciences, Inc. is a pioneer in the development and commercialization of highperformance microelectronic systems for cell-based assays. ACEA’s xCELLigence® systems are widely used in academic labs, government institutions, biotech and pharma companies around the world to study cell adhesion, cell migration/invasion, GPCR/RTK signaling, cell proliferation and compound/cell/viral-mediated cytotoxicity.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.